Does Primaquine Become The First Line in the Treatment of Uncomplicated Malaria in Coming Days?
| dc.contributor.author | Mosab Nouraldein Mohammed Hamad | |
| dc.date.accessioned | 2023-12-05T10:18:47Z | |
| dc.date.available | 2023-12-05T10:18:47Z | |
| dc.date.issued | 2022-02-27 | |
| dc.description.abstract | Background: Malaria is a major public health problem throughout human history, particularly in the tropical and subtropical countries. Primaquine, introduced in 1950, for preventing relapse and sterilizes infectious sexual plasmodia. Methods: A retrospective study was performed for 610 patients (250 were male and 360 were female), (all ages) to study the efficacy of Primaquine in the treatment of falciparum malaria after receiving this drug for five days. Results: Five hundred and ninety three patients (97.2 %) were completely recovered from malaria within 3 to 5 days after receiving Primaquine tablets. Conclusion: In our opinion Primaquine should become the first line as antimalarial drug soon later for uncomplicated malaria, because of its high efficiency against infections with Plasmodiumfalciparum and P.vivax active stages. | |
| dc.identifier.uri | https://ds.eaeu.edu.sd/handle/10.58971/645 | |
| dc.language.iso | other | |
| dc.publisher | جامعة الشيخ عبدالله البدري | |
| dc.title | Does Primaquine Become The First Line in the Treatment of Uncomplicated Malaria in Coming Days? |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Does_Primaquine_Become_The_First_Line_in_the_Treat.pdf
- Size:
- 466.75 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed to upon submission
- Description: